ATE515564T1 - Nicht herkömmliche nkt-zellen zur verwendung in der krebstherapie - Google Patents

Nicht herkömmliche nkt-zellen zur verwendung in der krebstherapie

Info

Publication number
ATE515564T1
ATE515564T1 AT08805044T AT08805044T ATE515564T1 AT E515564 T1 ATE515564 T1 AT E515564T1 AT 08805044 T AT08805044 T AT 08805044T AT 08805044 T AT08805044 T AT 08805044T AT E515564 T1 ATE515564 T1 AT E515564T1
Authority
AT
Austria
Prior art keywords
nkt cells
traditional
cancer therapy
cells
cd1d
Prior art date
Application number
AT08805044T
Other languages
English (en)
Inventor
Julien Marie
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE515564T1 publication Critical patent/ATE515564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08805044T 2007-10-05 2008-10-03 Nicht herkömmliche nkt-zellen zur verwendung in der krebstherapie ATE515564T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301434A EP2058388A1 (de) 2007-10-05 2007-10-05 Nicht-konventionelle NKT-Zellen zur Verwendung in der Krebstherapie
PCT/EP2008/063285 WO2009043931A1 (en) 2007-10-05 2008-10-03 Non-conventional nkt cells for use in cancer therapy

Publications (1)

Publication Number Publication Date
ATE515564T1 true ATE515564T1 (de) 2011-07-15

Family

ID=38800816

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08805044T ATE515564T1 (de) 2007-10-05 2008-10-03 Nicht herkömmliche nkt-zellen zur verwendung in der krebstherapie

Country Status (5)

Country Link
US (1) US20100303779A1 (de)
EP (2) EP2058388A1 (de)
AT (1) ATE515564T1 (de)
ES (1) ES2367726T3 (de)
WO (1) WO2009043931A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3250608B1 (de) * 2015-01-27 2024-08-21 LAVA Therapeutics N.V. Gegen cd1d gerichtete einzeldomänen-antikörper
TWI702290B (zh) 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
IL276374B2 (en) * 2018-01-30 2024-05-01 Res Inst Nationwide Childrens Hospital Transforming growth factor beta-resistant natural killer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009594A1 (en) * 2000-06-06 2004-01-15 Hiro Wakasugi Method for amplifying natural killer t cells
AU2003284994B2 (en) * 2002-10-25 2009-11-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods to prevent tumor recurrence by blockade of TGF-Beta
US7837990B2 (en) * 2005-03-28 2010-11-23 The Rockefeller University In vivo expanded NKT cells and methods of use thereof

Also Published As

Publication number Publication date
ES2367726T3 (es) 2011-11-08
EP2198014B1 (de) 2011-07-06
EP2058388A1 (de) 2009-05-13
WO2009043931A1 (en) 2009-04-09
US20100303779A1 (en) 2010-12-02
EP2198014A1 (de) 2010-06-23

Similar Documents

Publication Publication Date Title
PH12020550450A1 (en) Certain chemical entities, compositions and methods
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
DE602008005695D1 (de) Strahlentherapeutisches System zur strahlentherapeutischen Dosisverteilungsrekonstruktion
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112012019437A2 (pt) 5-alquinil-pirimidinas
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
ECSP11011213A (es) Compuestos heterocíclicos y métodos de uso
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
CR20120202A (es) Métodos y composiciones para tratar cáncer
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
BRPI0911525A2 (pt) composto, composição farmacêutica, método para preparar a mesma, uso de um composto, métodos para tratar uma doença ou distúrbio, para inibir a função de raf e para inibir proliferação celular
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
BRPI0719885B8 (pt) peptídeos peguilados como moduladores de receptores de pth, seus usos, e composição.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties